"The US Food and Drug Administration (FDA) has approved the tumor necrosis factor inhibitor adalimumab (Humira, AbbVie) for the treatment of moderate to severe hidradenitis suppurativa (HS), making it the first and only FDA-approved therapy"...
Metvixia Patient Information including How Should I Take
In this Article
- What is methyl aminolevulinate (Metvixia)?
- What are the possible side effects of methyl aminolevulinate (Metvixia)?
- What is the most important information I should know about methyl aminolevulinate (Metvixia)?
- What should I discuss with my health care provider before taking methyl aminolevulinate (Metvixia)?
- How is methyl aminolevulinate used (Metvixia)?
- What happens if I miss a dose (Metvixia)?
- What happens if I overdose (Metvixia)?
- What should I avoid while taking methyl aminolevulinate (Metvixia)?
- What other drugs will affect methyl aminolevulinate (Metvixia)?
- Where can I get more information?
What should I discuss with my health care provider before taking methyl aminolevulinate (Metvixia)?
You should not use this medication if you are allergic to methyl aminolevulinate, or if you have:
- an allergy to peanuts or almonds;
- an allergy to porphyrins; or
- if your skin is especially sensitive to light.
Before you are treated with methyl aminolevulinate, tell your doctor about all of your medical conditions.
FDA pregnancy category C. It is not known whether methyl aminolevulinate is harmful to an unborn baby. Before taking this medication, tell your doctor if you are pregnant or plan to become pregnant during treatment.
It is not known whether methyl aminolevulinate passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.
How is methyl aminolevulinate used (Metvixia)?
Methyl aminolevulinate topical is a cream that is applied to actinic keratosis skin lesions prior to red light treatment. Your doctor, nurse, or other healthcare provider will prepare your skin and apply this medication in a clinic setting.
Prior to application of methyl aminolevulinate, your skin lesions will be gently scraped to remove any scales or crusting. After the medication is applied, your caregiver will cover the treatment area with a bandage. You will need to leave this bandage in place for 3 hours.
During this 3-hour period, avoid exposure to cold temperatures and sunlight or bright indoor lights. Wear a wide-brimmed hat if you must be outdoors during this time.
After your bandaging is removed, any excess medication will be removed with a saline solution. You will then be ready to receive the light treatment.
You will be given eye-wear to protect your eyes during red light treatment.
You may feel a slight stinging or burning during light therapy. Tell your caregivers if you have any type of severe discomfort.
Methyl aminolevulinate and red light therapy is usually given in two sessions one week apart. Your treatment schedule may be different. Follow your doctor's instructions.
It may take several weeks before you notice improvement in your skin condition. Your doctor will need to check your treated skin 3 months after the end of your last treatment with methyl aminolevulinate.
Your skin lesions may need to be treated more than once, and they may come back after treatment. Talk to your doctor about the number of treatments needed to treat your condition.
Additional Metvixia Information
- Metvixia Drug Interactions Center: methyl aminolevulinate top
- Metvixia Side Effects Center
- Metvixia FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.